Skip to main content

Accuri Raises $5M in Venture Funds for Cytometer Launch

NEW YORK (GenomeWeb News) - Accuri Cytometers has netted $5 million in Series B financing from Baird Venture Partners and Arboretum Ventures, the company said today.
 
Accuri said it will use the money to fund further testing and to propel the full commercial launch of its C6 flow cytometer system.
 
The C6 system is targeted toward labs that require flow cytometry hardware but lack the funds to buy a high-priced instrument. Accuri plans to market the product for under $30,000.
 
The company said the system is currently in beta testing.
 
CEO Jennifer Baird said the funding will "carry Accuri through broader beta testing and position us for full commercial launch next year."
 
Accuri also said that BVP's Pete Shagory and Arboretum's Tim Peterson have joined its board of directors.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.